Impact of high-dose intravenous iron on treatment outcomes and cardiovascular events in hemodialysis patients with renal anemia

According to a recent study, the administration of high-dose intravenous iron may exhibit superior effects on hemoglobin levels, ferritin, transferrin saturation percentage, and the required dosage of erythropoietin in comparison to low-dose iron treatment. This study’s results were published in the journal Chronic Illness. 
In this meta-analysis study, 2422 patients with renal anemia under hemodialysis were enrolled. This study investigated the outcomes related to hemoglobin levels, transferrin saturation percentage, ferritin, erythropoietin dosage, and cardiovascular events.
The administration of high-dose intravenous iron could potentially result in an increase in transferrin saturation percentage, ferritin, and hemoglobin. Additionally, a lower erythropoietin dosage was required to sustain the optimal hemoglobin levels within the high-dose intravenous iron cohort compared to the low-dose intravenous iron cohort.
The above meta-analysis demonstrated that the administration of high-dose intravenous iron has been shown to yield superior outcomes in terms of hemoglobin levels, ferritin, and transferrin saturation percentage, and the required dosage of erythropoietin when compared to low-dose iron treatment.